---
title: "GEMPHARMATECH's approximately 206 million restricted shares will be listed and circulated on April 25"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236208506.md"
description: "According to the Zhitong Finance APP, GEMPHARMATECH announced that the restricted shares for this listing are held by some shareholders prior to the company's initial public offering, involving 4 shareholders, with a total of approximately 206 million shares, accounting for 50.2607% of the company's total shares. The lock-up period is 36 months from the date of the company's stock listing, and the restrictions will be lifted and the shares will be listed for trading on April 25, 2025"
datetime: "2025-04-16T10:23:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236208506.md)
  - [en](https://longbridge.com/en/news/236208506.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236208506.md)
---

# GEMPHARMATECH's approximately 206 million restricted shares will be listed and circulated on April 25

According to the Zhitong Finance APP, GEMPHARMATECH (688046.SH) announced that the restricted shares for this listing are held by some shareholders prior to the company's initial public offering, involving 4 shareholders, with a total of approximately 206 million shares, accounting for 50.2607% of the company's total shares. The lock-up period is 36 months from the date of the company's stock listing, and the restrictions will be lifted and the shares will be listed for trading on April 25, 2025

### Related Stocks

- [688046.CN](https://longbridge.com/en/quote/688046.CN.md)

## Related News & Research

- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [03:14 ETDatar Cancer Genetics recibe una histórica aprobación de la FDA estadounidense para CellDx-Tissue](https://longbridge.com/en/news/287174095.md)
- [Medivir enrolls first patient in Phase 2 FLEX-HCC fostrox-lenvatinib trial](https://longbridge.com/en/news/287172672.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy](https://longbridge.com/en/news/287059695.md)